Nikolai Kley, Orionis Biosciences CEO
September 20, 2023 11:37 AM EDT
Deals

Genen­tech gets gluey, pay­ing $47M up­front to Ori­o­n­is for de­grad­er dis­cov­ery deal

Lei Lei Wu

News Reporter

In its sec­ond deal an­nounced Wednes­day morn­ing, Roche’s Genen­tech is sign­ing up with Ori­o­n­is Bio­sciences for a mol­e­c­u­lar glue part­ner­ship in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

A new dawn for psy­che­delics? Com­pass could be the first to find out

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times